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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2015, TaiwanBackground: It remains unclear whether the benefit of postnatal corticosteroid as a respiratory
rescue therapy outweighs the potential harm of neurodevelopmental impairment (NDI) in very-
low-birth-weight infants at risk of bronchopulmonary dysplasia (BPD).
Methods: We reviewed the charts of very-low-birth-weight infants with oxygen dependency for
28 days or more and who survived until 18e22 months’ corrected age. Patients were divided
into the delayed (21 days after birth) dexamethasone therapy (DDT, nZ 71) and the control
(nZ 60) groups. NDI was defined by the presence of cerebral palsy, Bayley Mental or Psycho-
motor Developmental Index less than 70, deafness, or blindness.
Results: The DDT group was more premature and had worse respiratory morbidities before
(ventilator-dependent at 21 days, 69% vs. 17%) and after the DDT (moderate/severe BPD,
41% vs. 15%) than the control group. The risk of NDI did not differ between the DDT and the
control groups in the entire cohort (odds ratio and 95% confidence interval, 1.309 [0.530
e3.237]) or in the propensity-score-matched cohort (nZ 62; odds ratio and 95% confidence in-
terval, 1.344 [0.455e3.976]). However, in the subgroup of infants exposed to DDT, the cumu-
lative dexamethasone dose greater than 5.0 mg/kg was significantly associated with NDI.t of Pediatrics, Asan Medical Center Children’s Hospital, College of Medicine, University of Ulsan,
-gu, Seoul 138-736, Republic of Korea.
ul.kr (B.S. Lee).
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262 G. Lim et alConclusion: Among the very-low-birth-weight infants with BPD, there was no definitely harm-
ful effect of DDT on the neurodevelopmental outcome in the short term. However, considering
the potential harm of high cumulative doses of dexamethasone on the developing brain,
further studies are needed to determine the optimal dosage of DDT to be administered for
the prevention of BPD.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
In 2002, the American Academy of Pediatrics stated that
the routine use of corticosteroid therapy for preventing or
treating bronchopulmonary dysplasia (BPD) should be
discouraged1: this statement was made due to the concerns
regarding the risk of cerebral palsy (CP) and long-term
neurodevelopmental impairment (NDI) in preterm infants
who postnatally received corticosteroid therapy.2e5 Despite
this statement, surveys have revealed that a corticosteroid,
primarily dexamethasone, is still used as a rescue therapy
in 23% of extremely low-birth-weight infants under me-
chanical ventilation.6 Corticosteroid treatment is the most
effective treatment used in neonatal care as it can
dramatically alter the disease process and reduce the
severity of evolving or established BPD. In the meta-
analyses of the moderately early or late (>7 postnatal
days)7,8 or delayed (>21 postnatal days)9,10 use of dexa-
methasone therapy in preterm infants who were ventilator
dependent, both treatment strategies of rescue cortico-
steroid therapy were reported to facilitate extubation and
eventually decrease the severity of respiratory morbidity
and mortality in patients with BPD. However, it remains
unclear whether the benefit of late or delayed dexameth-
asone therapy (DDT) outweighs the potential harm in in-
fants with BPD, especially in terms of the long-term
neurodevelopmental outcome.
With the advances in early noninvasive ventilator stra-
tegies even in extremely low-gestational-age neonates,11,12
there is an increase in the proportion of infants who are not
ventilator-dependent beyond the early days but who still
require noninvasive ventilator support with or without the
requirement for supplemental oxygen. However, there are
no data regarding the effect of rescue steroid therapy in
this patient population with milder respiratory morbidity
seen on the respiratory or neurodevelopmental outcomes.
According to the current policy statement that allows the
use of corticosteroids in infants receiving maximum venti-
lator and oxygen support,13 it is not feasible to conduct a
prospective clinical trial addressing the effectiveness of
postnatal steroids in patients managed using a noninvasive
ventilator but who are still at high risk for moderate or
severe BPD. Therefore, this issue can only be addressed in
studies with a retrospective design.
The purpose of this study was to investigate the effect of
delayed dexamethasone treatment on the long-term neu-
rodevelopmental outcomes in premature infants with BPD
and in infants at high risk of BPD. To overcome the limita-
tions of retrospective analyses, we used propensity score(PS) analysis and the inverse-probability-of-treatment
weighted (IPTW) method to adjust for various clinical var-
iables, which might be associated with long-term neuro-
developmental outcomes.
2. Methods
2.1. Study design
This retrospective study includes infants with birth weight
less than 1500 g, gestational age less than 32 weeks, and
born in the neonatal intensive care unit of the Asan Medical
Center between January 2004 and December 2009. The
Institutional Review Board in our center approved this
retrospective study. Patients were diagnosed with BPD and
their severity was classified according to the National In-
stitutes of Health criteria [infants receiving supplemental
oxygen for 28 days with or without oxygen treatment at
36 weeks of postmenstrual age (PMA) or at the time of their
discharge home].14 All patients were assessed using a
developmental test at 18e22 months of corrected age (see
later discussion). The study groups were divided according
to the patients who were treated with dexamethasone at
21 days of life or later and using a designated protocol (DDT
group) and the patients who were not exposed to any sys-
temic or inhaled postnatal steroid therapy including dexa-
methasone, hydrocortisone, or budesonide nebulizer
(control group).
2.2. Postnatal steroid treatment and data
collection
Infants at high risk of BPD who were ventilator dependent
and those were receiving nasal continuous positive airway
pressure (CPAP) with FiO2 levels of 0.30 or more at the time
of the therapy were included in the analyses. The decision
to administer a postnatal systemic steroid was left to the
discretion of the attending neonatologist. According to the
treatment protocol of our medical center regarding the use
of a corticosteroid for prevention or treatment of BPD, only
dexamethasone was chosen as the treatment drug and the
treatment was initiated at 21 days of life or later. Dexa-
methasone was prescribed as part of one of the following
three protocols: (1) 14-day course with a cumulative dose
of 3.18 mg/kg; (2) 10-day course with a cumulative dose of
1.10 mg/kg; or (3) 7-day course with a cumulative dose of
1.59 mg/kg. Repeated or restarted courses of dexametha-
sone were considered in selected cases. Demographic
Table 1 Patient demographics and clinical data.
DDT treated Control p
(n Z 71) (n Z 60)
Birth weight (g) 871  206 971  171 0.003
Gestational age (wk) 26.4  1.5 27.8  1.4 0.000
Male gender 44 (62) 29 (48) 0.117
Chorioamnionitis 29 (40) 14 (23) 0.033
SGA 10 (14) 12 (20) 0.367
Prenatal steroid
completion
36 (51) 39 (65) 0.099
Apgar score at 1 min 3.5  1.7 4.2  1.7 0.022
Apgar score at 5 min 6.1  1.3 6.7  1.4 0.003
RDS 43 (61) 40 (67) 0.470
PDA ligation 23 (32) 7 (12) 0.005
Sepsis 21 (30) 6 (10) 0.006
Severe-grade
IVH/cystic PVL
11 (15) 8 (13) 0.727
NEC 9 (13) 2 (3) 0.055
ROP requiring laser 20 (28) 5 (8) 0.004
Ventilator dependency
at 21 d of life
49 (69) 10 (17) 0.000
Moderate or severe BPD 29 (41) 9 (15) 0.001
nCPAP at 36 wks of PMA 2 (3) 0 (0) 0.500
Under MV at 36 wks
of PMA
0 (0) 0 (0) NA
Duration of MV (d) 29  18 11  10 0.000
Duration of MV
including nCPAP (d)
38  20 24  14 0.000
Oxygen
supplementation (d)
72  39 43  14 0.000
Data are presented as number (%) or mean  standard devia-
tion.
BPD Z bronchopulmonary dysplasia; DDT Z delayed dexa-
methasone treatment; IVH Z intraventricular hemorrhage;
MV Z mechanical ventilation; NA Z not applicable;
nCPAP Z nasal continuous positive airway pressure;
NEC Z necrotizing enterocolitis; PDA Z patent ductus arte-
riosus; PMA Z postmenstrual age; PVL Z periventricular leu-
komalacia; RDS Z respiratory distress syndrome;
ROPZ retinopathy of prematurity; SGAZ small for gestational
age.
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multiple pregnancies. Clinical characteristics included his-
tological chorioamnionitis and the use of a complete course
of prenatal steroid therapy, Apgar scores at 5 minutes,
respiratory distress syndrome, ligation of patent ductus
arteriosus (PDA), culture-proven sepsis, severe-grade
intraventricular hemorrhage (Papile Grade 3 or 4), necro-
tizing enterocolitis (stage  2 according to the modified
Bell criteria), retinopathy of prematurity requiring laser
therapy, ventilator dependency at 21 postnatal days, the
severity of BPD at the 36-week PMA according to the Na-
tional Institutes of Health criteria,14 and the duration of the
use supplemental oxygen and a mechanical ventilator. To
evaluate the long-term neurodevelopmental effect of DDT,
detailed data on DDT use were also collected, including the
day of its commencement in terms of both the patient’s
postnatal age (PNA) and the PMA as well as the total cu-
mulative dexamethasone dose during the patient’s hospi-
talization period.
2.3. Neurodevelopmental outcome measurement
NDI was defined as the presence of CP, abnormal Bayley
Scales of Infant Development (BSID) II scores, blindness, or
deafness at 18e22 months of corrected age. CP was diag-
nosed by a rehabilitation doctor according to the definition
of a nonprogressive motor abnormalities characterized by
abnormal muscle tone of at least one extremity as well as
abnormal movement control or posture.15 The BSID II scores
were regarded as abnormal if the Mental Developmental
Index (MDI) or the Psychomotor Developmental Index (PDI)
values were less than 70.
2.4. Statistical analyses
A full nonparsimonious model was developed that included
the variables that may influence the decision to begin DDT.
These included demographic and clinical variables. Model
discrimination and model calibration were assessed using c-
statistics (Z0.830) and using HosmereLemeshow statistics
(c2 Z 5.2115, df Z 8, p Z 0.7348), respectively. After all
the PS matches were performed, the baseline variables
between the two groups were compared. Continuous vari-
ables were compared using the paired t test (or the Wil-
coxon signed-rank test) and categorical variables were
compared using the McNemar test. In the PS-matched
cohort, the risks of each outcome variables were
compared using logistic regression with generalized esti-
mating equations that accounted for the clustering of
matched pairs. The adjustment for ventilator dependency
at 21 days, according to the weighted logistic regression
using the IPTW method, was applied. With this technique,
the weights for the control group were the inverse of
(1 e PS), and weights for the DDT group were the inverse of
the PS. Stratified logistic regression was used for the anal-
ysis of the differential influence of the cumulative dexa-
methasone dose on the NDI in infants with differing severity
of their respiratory condition at 21 days of life. SAS version
9.2 (SAS Institute, Cary, NC, USA) was used for all statistical
analyses. A p value less than 0.05 was considered
significant.3. Results
3.1. Study population and neonatal outcomes
A total of 131 infants were evaluated during follow-up at
18e22 months of corrected age after exclusion of the infants
who received the dexamethasone therapy before 21 post-
natal days (nZ 6) and those infants who were lost to follow-
up at the time of the assessment of NDI (nZ 13). Compared
with the control group, the infants in the DDT group were
more premature and less healthy at birth and had a higher
incidence of chorioamnionitis. The DDT group also had a
significantly greater number of neonatal morbidities such as
PDA ligation, sepsis, and retinopathy of prematurity requiring
laser therapy, as well as severe respiratory morbidities
including moderate or severe BPD seen at the 36-week PMA
(Table 1). DDTwas started at 35.7 11.3 (range, 21e75) days
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before 35 weeks of PMA except for one case). The cumulative
DDT dose was 3.6  2.1 mg/kg (range, 1.10e10.9 mg/kg).
There was no association between the cumulative DDT dose
and the postnatal day on which DDT began (r Z 0.165,
pZ 0.170). The cumulative DDT dose was significantly asso-
ciated with a worse respiratory status before and after DDT;
the mean cumulative dose was higher in those patients who
were under ventilator therapy at 21 days (4.09 2.24 mg/kg)
than in the patients receiving nasal CPAP (2.48 1.37 mg/kg;
p< 0.001). In addition, the mean cumulative dose was higher
in the infants with moderate or severe BPD (4.92  2.36 mg/
kg) than in those with mild BPD (2.67  1.35 mg/kg) at
36 weeks of PMA (p< 0.001). The cumulative dexamethasone
dose was significantly associated with the longer duration of
mechanical ventilator use (r Z 0.61, p Z 0.001), days of
dexamethasone exposure (rZ 0.904, p< 0.001), or the total
duration of positive pressure ventilation including nasal CPAP
(rZ 0.457, pZ 0.012). In the DDT group, 49 (69%) patients
were under ventilator treatment at 21 days of life. At the time
of DDT, 45 (63%) were under ventilator treatment and others
were receiving nasal CPAP with FiO2 levels of 0.30 or more
(n Z 26; 37%). Meanwhile, at 36 weeks of PMA, when all
except for one case had come off DDT, none was under
ventilator therapy, and only two cases were managed with
nasal CPAP.
3.2. Neurodevelopmental outcomes
In the entire patient cohort, the overall incidence of CP and
NDI was 5% (nZ 7) and 22% (nZ 29), respectively. There
were no patients who were diagnosed with blindness or
deafness. Detailed information about each NDI component
is as follows: MDI less than 70 only (nZ 6); PDI less than 70
only (n Z 10); both MDI and PDI less than 70 (n Z 7); CPTable 2 Results of univariate and multivariate analyses of risk fa
infants with bronchopulmonary dysplasia.
Infants with BPD (nZ 131)
Crude OR (95% CI)
Birth weight, g 0.998 (0.996e1.000)
Apgar score at 1 min 0.812 (0.633e1.040)
RDS 2.683 (1.006e7.158)
Severe-grade IVH 4.140 (1.490e11.506)
ROP requiring laser therapy 3.040 (1.188e7.662)
Duration of ventilator, d 1.029 (1.005e1.053)
DDT 1.513 (0.650e3.521)
Data are presented as odds ratio (95% confidence interval).
Neurodevelopmental impairment was defined as the presence of CP o
Clinical data included in the analysis were birth weight (g), gestatio
course of antenatal corticosteroid, Apgar score at 1 and 5 minutes, RD
requiring laser therapy, moderate-to-severe BPD at 36-week PMA, dura
DDT, cumulative DDT dose (mg/kg), PNA at DDT (days), and PMA at DD
DDT are listed in the table.
BPD Z bronchopulmonary dysplasia; CI Z confidence interval; C
IVHZ intraventricular hemorrhage; MDIZ Mental Developmental Inde
OR Z odds ratio; PDA Z patent ductus arteriosus; PMA Z postmens
drome; ROP Z retinopathy of prematurity; SGA Z small for gestatio
* Adjusted with birth weight, Apgar score at 1 min, RDS, severe-gradwith MDI less than 70 (nZ 1); and CP with both MDI and PDI
less than 70 (nZ 5). Although six of the seven patients with
CP were in the DDT group, the rate of CP and NDI did not
differ between the DDT group and the control group: CP (6
vs. 1, p Z 0.124) and NDI (18 vs. 11, P Z 0.401).
DDT was not associated with the NDI in neither univari-
ate nor multivariate analysis in the entire cohort (Table 2).
Similarly, DDT did not adversely affect the neuro-
developmental outcome in a multivariate analysis with
covariate adjustment using the PS analysis in the cohort of
31 patients in each group and with the IPTW method used in
the entire cohort (Tables 3 and 4). In the subgroup of in-
fants exposed to DDT (nZ 71), only the cumulative dose of
DDT was significantly associated with NDI after multivariate
analysis (Table 5). To investigate the critical dose of DDT
required for predicting NDI, the cumulative dexamethasone
dose was stratified by arbitrary cutoff values of 2, 3, 4, 5,
and 6 mg/kg. When using the same variables included in
Table 5, only the cumulative dexamethasone dose greater
than 5 mg/kg was significantly associated with NDI in
multivariate analysis (odds ratio Z 8.749; 95% confidence
interval Z 1.177e29.878).
4. Discussion
In this study, the postnatal dexamethasone therapy, if
started after 21 days of life, was not associated with the
long-term neurodevelopmental outcomes in the entire
cohort of preterm infants at high risk of BPD. As the deci-
sion to select patients for DDT was not randomized, we
used PS-matching analysis and the IPTW method to mini-
mize the potential bias affecting the treatment assignment
in this study. Despite our concern regarding the potential
adverse effect of postnatal steroid use on neuro-
developmental outcomes, extreme preterm infants at highctors for neurodevelopmental outcome in the entire cohort of
Neurodevelopmental impairment
p Adjusted OR (95% CI)* p
0.081 0.998 (0.996e1.001) 0.269
0.099 0.941 (0.700e1.266) 0.689
0.049 2.760 (0.943e8.083) 0.064
0.006 3.557 (1.163e10.876) 0.026
0.021 1.766 (0.585e5.330) 0.313
0.019 1.011 (0.982e1.041) 0.927
0.337 0.952 (0.337e2.693) 0.927
r MDI < 70 or PDI < 70.
nal age (weeks), male gender, chorioamnionitis, SGA, complete
S, PDA ligation, sepsis, severe-grade (Grade 3 or 4) IVH, NEC, ROP
tion of ventilators (days), duration of oxygen requirement (days),
T (days). Only the variables with p < 0.1 in crude odds ratio and
P Z cerebral palsy; DDT Z delayed dexamethasone therapy;
x; MVZmechanical ventilation; NECZ necrotizing enterocolitis;
trual age; PNA Z postnatal age; RDS Z respiratory distress syn-
nal age.
e IVH, ROP requiring laser therapy, duration of ventilator and DDT.
Table 3 Baseline characteristics of the propensity score-
matched patients.
DDT treated Control p
(nZ 31) (nZ 31)
Gestational age (wk) 27.1  1.4 27.2  1.1 0.689
Birth weight (g) 912.7  222.3 960.7  173.9 0.296
Apgar score at 5 min 6.5  1.2 6.6  1.3 0.604
Chorioamnionitis 9 (29) 9 (29) 1.000
Completed
betamethasone
18 (58) 17 (55) 1.000
Respiratory
distress syndrome
17 (55) 18 (58) 1.000
PDA ligation 7 (23) 4 (13) 1.000
Ventilator dependency
at 21 d of life
10 (32) 10 (32) 1.000
Data are presented as number (%) or mean  standard devia-
tion.
DDT Z delayed dexamethasone therapy; PDA Z patent ductus
arteriosus.
Delayed dexamethasone therapy and neurodevelopment 265risk of BPD are still treated with postnatal corticosteroids,
usually with dexamethasone.16e19 In fact, the decreased
use of postnatal steroids has not been consistently associ-
ated with improved neurodevelopmental outcomes. As
previously mentioned, in the Cochrane meta-analysis by
Halliday et al,8,9,20 the use of postnatal steroids after 7 days
of life was not associated with the adverse, long-term
neurodevelopmental outcome but it rather had a benefi-
cial effect on the neurodevelopmental outcome in
survivors.10,21
In our study, the cumulative dexamethasone dose was
significantly associated with NDI in DDT-treated infants.
This is in contrast to the results in a recent meta-analysis
including several randomized controlled studies composed
of moderately early or delayed dexamethasone pro-
tocols.10,22 However, in those studies the direction of risk
regarding the neurodevelopmental outcomes differed
depending on the onset of dexamethasone therapy.10 In the
subgroup metaregression analysis among the clinical trials
of moderately early onset treatment, a significant inverseTable 4 Univariate analysis and multivariate logistic
regression, propensity-score-matched analyses, and the
inverse-probability-of-treatment weighted method of the
association between the DDT and the neurodevelopmental
outcomes in infants with bronchopulmonary dysplasia.
Neurodevelopmental
impairment (event Z 29)
Event Odds ratio (95% CI) p
Crude (nZ 131) 29 1.513 (0.650e3.521) 0.337
Multivariate (nZ 131) 29 1.309 (0.530e3.237) 0.560
Propensity-matched
set (nZ 62)
20 1.344 (0.455e3.976) 0.593
IPTW (nZ 131) 29 1.314 (0.446e3.871) 0.620
CI Z confidence interval; DDT Z delayed dexamethasone
therapy.relationship was observed between the cumulative dose of
dexamethasone and the risk for combined outcomes of
death or CP and an MDI less than e2 standard deviation.
Meanwhile, although not significant, the analysis among the
trials of delayed treatment onset revealed the opposite
trend of an increasing risk of NDI with an increase in the
cumulative doses, which was in concordance with the ob-
servations in our patient cohort. In another study that
measured the brain volume at term equivalent age in
extremely low-birth-weight infants, the patients exposed
to dexamethasone therapy after a PNA of 4 weeks had
smaller cerebral tissue volume than the control group, even
though the cumulative dexamethasone dose was lower (a
mean dose of 2.8 mg/kg) than in the previously mentioned
meta-analysis and in our study.23 It is unclear why the
impact of cumulative dexamethasone doses on the long-
term neurodevelopmental outcome differs depending on
the treatment onset in infants at high risk of BPD. One
possible explanation is that the maturational stage of
developing brain is an independent determinant of sus-
ceptibility to the various causes of brain insult, including an
oxygen-free radical, hemodynamic instability, and inflam-
matory cytokines.24 However, in our study, neither the PMA
nor the PNA at which DDT was started was associated with
NDI. Another speculation is that the severity of BPD per se,
as defined by the duration of respiratory support or the
need for supplemental oxygen, or both, which could be
attenuated by postnatal dexamethasone therapy, is an in-
dependent risk factor for neurodevelopmental out-
comes.25,26 In our study, the severity of respiratory
morbidity, including the duration of mechanical ventilation
and nasal CPAP, was also associated with the cumulative
dexamethasone doses. Compared with the early or
moderately early dexamethasone therapy, DDT is supposed
to be administered to those patients at a higher risk of BPD
as they are exposed to a longer period of the inflammatory
process caused by ventilator-induced lung injury or sup-
plemental oxygen. Therefore, higher cumulative doses
and/or a longer duration of dexamethasone therapy is
required to extubate those patients from the ventilator or
to step down the level of respiratory support. Although in
our study the effect of the severity of respiratory morbidity
was adjusted by the PS or IPTW analysis, the complex in-
teractions between the severity of BPD and treatment-
related risk factors that might affect neurodevelopmental
outcomes are too complex to be fully explained.
Our study was a retrospective one and thus was not
originally aimed to evaluate efficacy of DDT on the attenu-
ation of respiratory morbidities in the BPD. As expected,
compared with the control group, the patients in the DDT
group were more premature and had worse respiratory
morbidities from the early weeks and at 36 weeks of PMA
when most patients in the DDT group had completed the
DDT. The association between the cumulative dose of DDT
and a worse respiratory status does not mean that DDT has
no efficacy on the attenuation of respiratory morbidity but
rather reflects the caregiver’s preference to choose the DDT
protocol consisting of higher cumulative doses depending on
the severity of respiratory status. The overall rate of BPD at
36 weeks of PMA (41%) in the DDT group was similar to the
rate (44.8%) of a recent systemic review, which confirmed
the respiratory benefits of late dexamethasone therapy in
Table 5 Results of univariate and multivariate analyses of risk factors for neurodevelopmental outcome in infants with DDT-
treatment group.
Infants with BPD exposed to DDT (nZ 71) Neurodevelopmental impairment
Crude OR (95% CI) p Adjusted OR (95% CI)* p
Birth weight (g) 0.996 (0.993e1.000) 0.025 0.997 (0.992e1.002) 0.997
Apgar score at 1 min 0.741 (0.524e1.049) 0.091 0.884 (0.573e1.366) 0.884
Ventilator dependency at 21 d of life 1.228 (0.377e4.003) 0.734 0.224 (0.038e1.332) 0.224
ROP requiring laser therapy 2.733 (0.882e8.466) 0.081 1.810 (0.387e8.471) 0.451
Severe-grade IVH 3.013 (0.792e11.464) 0.106 3.739 (0.758e18.449) 0.105
Small for gestational age 3.013 (0.792e11.464) 0.106 1.307 (0.182e9.371) 0.790
Cumulative dose of dexamethasone 1.460 (1.110e1.919) 0.007 1.396 (1.002e1.946) 0.049
Data are presented as odds ratio (95% confidence interval).
BPD Z bronchopulmonary dysplasia; CI Z confidence interval; DDT Z delayed dexamethasone therapy; IVH Z intraventricular hem-
orrhage; OR Z odds ratio; ROP Z retinopathy of prematurity; SGA Z small for gestational age.
* Adjusted with birth weight, Apgar score at 1 minute, ventilator dependency at 21 days, ROP requiring laser therapy, severe-grade
IVH, SGA, cumulative dose of dexamethasone.
266 G. Lim et alpreterm infants.7 In addition, the rate of severe BPD was
remarkably low (3%) and none was ventilator dependent at
36 weeks of PMA. These findings indirectly demonstrate
considerable efficacy of DDT in terms of facilitating extu-
bation and attenuation of BPD severity in our cohort.
By PS-matched and IPTW analyses, we indirectly
demonstrated the risk of DDT on the long-term neuro-
developmental outcomes unaffected by the respiratory
status at 21 days of life. Of course, this result cannot justify
the use of DDT in the group of patients who were not
ventilator dependent. However, besides the ventilator de-
pendency, the severity of chronic respiratory morbidity
such as home oxygen therapy is another risk factor of long-
term developmental impairment.25 To our surprise, in
terms of the neurodevelopmental outcomes, the advantage
of the early nasal CPAP approach over conventional venti-
lator therapy is not clear in very premature infants.27,28
Whether the attenuation of respiratory morbidity by DDT
can further reduce the risk of NDI, especially in infants with
BPD, remains a topic of a well-designed controlled trial.
There are several limitations to our study. First, inherent
to the retrospective design, the baseline characteristics of
the patients, including anthropometric parameters and,
most importantly, the respiratory morbidities before the
infants received DDT differed between the study groups;
however, the influence of candidate variables, which were
potentially associated with DDT and NDI, was considered
and statistically corrected by multivariate analysis and the
PS-matched set. Second, infants who died or were lost to
follow-up before the time of the developmental testing
were excluded from the analysis; however, the rate of
follow-up loss was relatively low considering the retro-
spective design of our study and it did not differ between
the study groups. Third, the single outcome variable of NDI,
which was defined by the presence of CP, abnormal BSID II
score, blindness, and deafness, may not suitable for the
assessment of the differential influence of DDT on the
developmental component of motor and cognitive dys-
functions. Indeed, the rate of CP was substantially higher in
the DDT group versus the control group, although it did not
reach statistical significance. Fourth, the risk of dexa-
methasone on NDI was only determined by the cumulativedoses and not by the treatment of duration because the
designated protocols were sometimes halted or repeated
for clinical decision. Finally, the sample size of our single
center study was relatively small, with less than 30 cases in
the NDI group, which might not be an adequate number to
analyze several factors, particularly by logistic regression.
However, enrollment of more cases by extending the study
period was not feasible because the unit policy for steroid
treatment and developmental follow-up was changed for
patients with BPD.
In conclusion, DDT in the very-low-birth-weight infants
at high risk of BPD was not associated with NDI at 18e22
months of corrected age. However, an optimal protocol for
cumulative doses of dexamethasone, approximately less
than 5.0 mg/kg, should be considered to minimize the risk
of NDI. Further well-controlled, prospective studies are still
needed to determine the optimal time and dosing strate-
gies of rescue dexamethasone therapy for premature in-
fants at a high risk of both BPD and long-term, adverse,
neurodevelopmental outcomes.Conflicts of interest
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